|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In light of the increasing use of G-CSF and GM-CSF in adjuvant tumor therapy, our data, as well as those discussed for head-and-neck tumors and gliomas, warrant a careful re-evaluation of the clinical application of both factors.
|
10597195 |
1999 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Cancer cells expressing GM-CSF and its receptor did not develop into tumors when autografted into immunocompetent mice.
|
23108143 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The granulocyte-macrophage colony-stimulating factor-induced enhancement of tumor cell proliferation was mediated by bone-marrow-derived cells in vitro.
|
28240048 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In vivo vaccination using tumor cells transduced ex vivo with DISC-IL2 or DISC-GMCSF resulted in protection against subsequent tumor challenge (P < .01), with DISC-GMCSF-transduced, irradiated tumor cells showing the greatest effects (P < .001).
|
11023201 |
2000 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In our study, GM-CSF seemed to have advantage for tumor proliferation and invasion in lung cancer cells.
|
16820947 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The purpose of this study was to examine the tumor specificity, cytotoxicity, and granulocyte macrophage colony-stimulating factor expression of CG0070, a conditionally replicating oncolytic adenovirus, in human bladder transitional cell carcinoma (TCC) cell lines and determine its antitumor efficacy in bladder TCC tumor models.
|
16397056 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Ad5/3-E2F-Δ24-GMCSF (CGTG-602) was engineered to contain a tumor specific E2F1 promoter driving an E1 gene deleted at the retinoblastoma protein binding site ("Δ24").
|
25714011 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We tested immune-modulating doses of chemotherapy in combination with a granulocyte/macrophage-colony stimulating factor (GM-CSF)-secreting, HER-2/neu (neu)-expressing whole-cell vaccine as a means to treat existing mammary tumors in antigen-specific tolerized neu transgenic mice.
|
11325840 |
2001 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Granulocyte-macrophage colony-stimulating factor (GM-CSF) gene-transduced, irradiated tumor vaccines induce potent, T-cell-mediated antitumor immune responses in preclinical models.
|
9108457 |
1997 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
CONCLUSIONS Preoperative BMI > 25 kg/m<sup>2</sup> and tumor location in the posterior fossa were associated with higher rates of postoperative CSF leak.
|
28598276 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This work indicates that LMP1-mediated glycolysis regulates IL-1β, IL-6 and GM-CSF production through the NLRP3 inflammasome, COX-2 and P-p65 signaling pathways to enhance tumor-associated MDSC expansion, which leads to tumor immunosuppression in NPC.
|
28732079 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A positive correlation between GM-CSF and IL6 expression and disease course was observed by meta-analyses of the clinical data.<b>Conclusions:</b> Our studies indicate a significant reappraisal of the role of IL6 and GM-CSF in metastasis and implicate CAFs as the "henchmen" for cancer cells in producing an immunosuppressive tumor ecological niche.
|
29959142 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Chimeric CLL-1 antibody fusion proteins containing granulocyte-macrophage colony-stimulating factor or interleukin-2 with specificity for B-cell malignancies exhibit enhanced effector functions while retaining tumor targeting properties.
|
9192768 |
1997 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Direct oncolysis plus granulocyte-macrophage colony-stimulating factor (GM-CSF) expression also stimulates shutdown of tumour vasculature and antitumoral immunity.
|
18495536 |
2008 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Here, we evaluated safety and immunogenicity of Apo-DC in combination with lenalidomide, granulocyte-macrophage colony-stimulating factor (GM-CSF), and low-dose cyclophosphamide (CTX).
|
29569742 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
It is thought that the production of colony-stimulating factor by neoplasms is the most potent cause of tumour-induced leukocytosis; several mechanisms have been suggested to explain this.
|
7691144 |
1993 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Further, tumors treated with oAd- and DC-loaded gel (oAd+DC/gel) showed a significantly greater expression level of IL-12, GM-CSF, and interferon-γ (IFN-γ) than either single treatment (oAd or DC) or oAd in combination with DC (oAd+DC), resulting in efficient activation of both endogenous and exogenous DCs, migration of DCs to draining lymph nodes, and tumor infiltration of CD4<sup>+</sup> and CD8<sup>+</sup> T cells.
|
28336378 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A universal granulocyte-macrophage colony-stimulating factor-producing bystander cell line for use in the formulation of autologous tumor cell-based vaccines.
|
10466632 |
1999 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Patients administered 100% treated cells (i.e., with a preparation of tumor cells that had all been exposed to GM-CSF DNA transfection) had a more extensive lymphocytic infiltrate at the vaccine site than did patients given 10% treated cells (a preparation of tumor cells in which 10% had been exposed to GM-CSF transfection) or nontreated tumor.
|
12396624 |
2002 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We investigated plasma levels of selected hematopoietic cytokines: stem cell factor (SCF), granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF), and macrophage colony-stimulating factor (M-CSF) and the tumor marker cancer antigen (CA 125) in epithelial ovarian cancer patients as compared with control groups: benign ovarian tumor patients (cysts) and healthy subjects.
|
22988839 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
An adenovirus that expresses both interleukin (IL)-12 and granulocyte-macrophage colony-stimulating-factor (GM-CSF) has been proven to be very effective in treating several tumors, but causes serious normal tissue toxicities.
|
23352035 |
2013 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We have recently demonstrated that a 4-in-1 gene therapy strategy that contains two anti-angiogenic genes [endostatin and pigment epithelium-derived factor] and two cytokine genes [granulocyte macrophage colony-stimulating factor and interleukin 12] has a considerable antitumor effect on large tumors in a woodchuck hepatoma model.
|
22266191 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
It has been demonstrated that the HPV 16 E6/E7 oncoproteins can serve as tumour rejection antigens (TRA) and that the HPV 16-associated tumour cells can be genetically modified with DNA encoding immunostimulatory cytokines (IL-2, IL-12, GM-CSF) or other immunostimulatory molecules, used for vaccination, and inhibit tumour growth.
|
18473731 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In contrast, vaccination with granulocyte/macrophage colony-stimulating factor (GM-CSF)-transduced tumor cells, previously shown to induce potent antitumor immunity in standard tumor challenge assays, led to a decreased therapeutic effect in the metastasis model and no effect in the subcutaneous tumor model.
|
10811863 |
2000 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In MAP/GM-CSF vaccinated animals, a cellular immune response was detected in association with the appearance of CD4+ and CD8+ T cells at the tumor site.
|
15340764 |
2005 |